OTLK News and Press, Outlook Therapeutics Inc. From 05/16/24

2024-05-16 14:35:26 ET Outlook Therapeutics, Inc. (OTLK) Q2 2024 Earnings Conference Call May 16, 2024 8:30 AM ET Company Participants Jenene Thomas - IR, JTC Team, LLC Russell Trenary - President & CEO Lawrence Kenyon - Chief Financial Officer Conferen...

2024-05-16 12:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-15 17:39:14 ET More on Outlook Therapeutics Outlook Therapeutics: De-Risked Regulatory Tracks Are Lining Up For Possible ONS-5010 Approval Outlook Therapeutics shares rise after 'buy' rating from BTIG Outlook Therapeutics stock jumps as EU backs new wet AMD t...

Positive opinion received from Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for ONS-5010/LYTENAVA™ (bevacizumab gamma) United Kingdom (UK) Marketing Authorization Application (MAA) submitted NORSE EIGHT fully underway in the U...

2024-05-15 11:47:59 ET Major earnings expected before the bell on Thursday include: Baidu ( BIDU ) Deere & Co. ( DE ) JD.com( JD ) Under Armour ( UAA ) Walmart ( WMT ) Other earnings slated for release before Thursday's open include: ...

UK submission for national MAA review follows recently received positive opinion from Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) concerning the authorization of ONS-5010/LYTENAVA™ (bevacizumab gamma) ISELIN, N.J., May 13, 2024 (GL...

ISELIN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced that it will report ...

ISELIN, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced it will present at t...

ISELIN, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced it will present at...

2024-04-26 16:40:00 ET More on Outlook Therapeutics Outlook Therapeutics: De-Risked Regulatory Tracks Are Lining Up For Possible ONS-5010 Approval Outlook Therapeutics shares rise after 'buy' rating from BTIG Outlook Therapeutics stock jumps as EU backs new wet AMD t...